Our study demonstrated increased expression of CD155 in urothelial carcinoma of the urinary bladder with advancing stage, suggesting its potential as a therapeutic target. Additionally, CD155 expression correlated positively with PD-L1 expression, indicating that some patients might benefit from a combined blockade of both targets.
Shibel et al. (Sun,) studied this question.